Key result
Vena cava filters carry ~2.5-fold higher recurrent VTE risk vs. anticoagulation in cancer patients.
Meta-Analysis (n=35,333)
Answers are grounded in this paper and cite their sources.
BACKGROUND: Results from cohort studies evaluating the benefit in prevention of recurrent Venous Thromboembolism in cancer population are heterogeneous and controversial. OBJECTIVE: To determine the effectiveness and harms of vena cava filters alone or combined with anticoagulation to prevent the risk of recurrent venous thromboembolism in patients with cancer-related venous thromboembolism. MATERIALS AND METHODS: A search strategy was conducted in the MEDLINE, CENTRAL, EMBASE and LILACS databases. Searches were also conducted in other databases and unpublished literature. Clinical trials were included without language restrictions. The risk of bias was evaluated with the Cochrane Collaboration's tool and a modified version for cohort studies. An analysis of fixed effects was conducted. The primary outcome was recurrent venous thromboembolism. The secondary outcomes were overall survival and adverse effects. The measure of the effect was the risk ratio with a 95% confidence interval. RESULTS: Seven studies were included in the qualitative and quantitative analysis. 35,333 patients were found among the seven studies. A low risk of bias was shown for most of the study items. The overall risk ratio (RR) for recurrent venous thromboembolism was 2.53 95%CI (1.35-4.75) favoring anticoagulation compared with vena cava filter. CONCLUSION: Vena cava filter did not show benefits for recurrent venous thromboembolism prevention in the cancer-patients population.
No takes yet. Share an insight, caveat, or question.
Rojas‐Hernandez et al. (2018) conducted a meta-analysis in Cancer-related venous thromboembolism (n=35,333). Vena cava filter alone or combined with anticoagulation vs. Anticoagulation was evaluated on Recurrent venous thromboembolism (RR 2.53, 95% CI 1.35-4.75). Vena cava filters showed no benefit over anticoagulation for preventing recurrent VTE in cancer patients, favoring anticoagulation.
Synapse has enriched 10 related papers. Consider them for comparative context: